Boehringer Ingelheim

(COMUNICADO DE PRENSA) INGELHEIM, 17-Jan-2023 — /EuropaWire/ — Boehringer Ingelheim, una de las principales compañías farmacéuticas del mundo impulsadas por la investigación con 130 años de experiencia, ha anunciado que ha sido nombrada “Global Top Employer” por tercer año consecutivo por … Read the full press release →

(PRESS RELEASE) STOCKHOLM, 15-Feb-2019 — /EuropaWire/ — TeffLand has launched new lines of grain and flour for the popular Teff cereal. The new products maintain all of Wheat’s advantages and none of its disadvantages. Unlike its Wheat counterpart, Teff flours make … Read the full press release →

Metacam® 0.5mg/ml Oral Suspension for Cats is now also approved in Europe for alleviation of mild to moderate post-operative pain associated with soft tissue surgery in guinea-pigs True market need to provide relief after painful  procedures and surgeries Boehringer Ingelheim is … Read the full press release →

STUTTGART, 12-Feb-2018 — /EuropaWire/ — Ruth Schimanowski took over management of the German Centre Beijing, a member of LBBW group. The German Centre has been supporting German companies in China with offices, advice and networks since 1999. She is the … Read the full press release →

Collaboration and licensing agreement focused on investigating up to three targets and has a potential transactional value of up to EUR 307 million, excluding royalties Expands Boehringer Ingelheim’s comprehensive R&D programme in non-alcoholic steatohepatitis (NASH) and fibrotic liver disease with … Read the full press release →

The programme was set up by the International Society of Feline Medicine (ISFM), the veterinary division of the charity International Cat Care (ICC) Boehringer Ingelheim will promote the programme and develop informational tools and services to grow veterinarians’ and cat … Read the full press release →

61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1  Survey underlines the importance of appropriate support and coping mechanisms for patients living with IPF1 Healthcare teams emphasise the need of a strong support network … Read the full press release →

New start-up as platform for digital transformation in data science, agile software development and user experience design Improvement of  human and animal health with innovative digital solutions BI X offers 50 new jobs at the company’s headquarters Investment of 10 … Read the full press release →

Both companies will become global leaders in two different sectors of the pharmaceutical market Paris (France) and Ingelheim (Germany), 03-Jan-2017 — /EuropaWire/ — Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an … Read the full press release →

360 million people worldwide suffer from disabling hearing loss with no effective treatment available New collaboration with China Southeast University is part of the Research Beyond Borders (RBB) initiative, which aims to explore emerging science within and beyond Boehringer Ingelheim’s … Read the full press release →

LIVERPOOL, 25-Nov-2016 — /EuropaWire/ — A pioneering University of Liverpool research team have published a study that identifies the mechanism in the human body that causes resistance of pancreatic cancer cells to chemotherapy. Pancreatic cancer is one of the leading … Read the full press release →

PARIS, 04-Oct-2016 — /EuropaWire/ — Sanofi today announced the appointment of Alan Main as Executive Vice President Consumer HealthCare, effective October 1st, 2016. Mr. Main will be a member of the Executive Committee and lead a newly created Consumer Healthcare … Read the full press release →

After 12 weeks, approximately twice as many patients with moderate-to-severe Crohn’s disease, the majority of whom had previously failed treatment with one or more TNF antagonists,  achieved clinical remission with risankizumab compared with placebo1 Endoscopic remission was achieved in 15% … Read the full press release →

• Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases.1,2 • Approval of Giotrif® is based on results of the LUX-Lung 8 study, … Read the full press release →

• A single 5g dose of idarucizumab immediately reversed the anticoagulant effect of dabigatran in all patients evaluated • Results based on analyses of high-risk patients from RE-VERSE AD™ study • Data presented at ACC 2016 Scientific Session and Expo … Read the full press release →

Ingelheim, Germany, 03-Mar-2016 — /EuropaWire/ — For the ninth time, Boehringer Ingelheim Animal Health has funded independent European research projects related to Porcine Circovirus Type 2 (PCV2) infection and associated diseases. Over the past nine years, 26 research projects have been … Read the full press release →

• Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib superior in reducing the risk of lung cancer progression and the risk of treatment failure both by 27% compared to gefitinib1 • More patients on afatinib were free of … Read the full press release →

Ingelheim, 20-11-2015 — /EuropaWire/ — Boehringer Ingelheim has been named one of the most innovative companies worldwide in 2015. For the first time, the research-driven pharmaceutical company ranked among the 100 leading global innovators named by news agency Thomson Reuters. Thomson … Read the full press release →

Your Time campaign calls for earlier action in COPD WHO expects COPD to be the third leading cause of death worldwide by 2030 – exceeded only by heart disease and stroke1 By the time most people know they have COPD, … Read the full press release →

OTEMTO® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto® Respimat® right from the initial stage when patients first need maintenance therapy* Head-to-head ENERGITO® study shows superior lung function improvements with Spiolto® Respimat® versus LABA/ICS FDC AMSTERDAM, 29-9-2015 … Read the full press release →